Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -120.59% | -68.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -120.59% | -68.09% | |||
| Cost of Revenue | 16.64% | -10.24% | |||
| Gross Profit | -26.13% | -2.63% | |||
| SG&A Expenses | -8.13% | -3.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.38% | -8.64% | |||
| Operating Income | -17.03% | -0.90% | |||
| Income Before Tax | -19.23% | -2.47% | |||
| Income Tax Expenses | -- | -70.59% | |||
| Earnings from Continuing Operations | -19.18% | -2.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.18% | -2.36% | |||
| EBIT | -17.03% | -0.90% | |||
| EBITDA | -18.00% | -1.06% | |||
| EPS Basic | -18.94% | -2.08% | |||
| Normalized Basic EPS | -18.99% | -2.19% | |||
| EPS Diluted | -18.94% | -2.08% | |||
| Normalized Diluted EPS | -18.99% | -2.19% | |||
| Average Basic Shares Outstanding | 0.21% | 0.28% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||